Compare SMG & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMG | NAMS |
|---|---|---|
| Founded | 1868 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2012 | N/A |
| Metric | SMG | NAMS |
|---|---|---|
| Price | $62.56 | $33.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $73.00 | $46.75 |
| AVG Volume (30 Days) | ★ 913.3K | 811.1K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | ★ 504.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,016,500,000.00 | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | $2.63 | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.17 | N/A |
| 52 Week Low | $45.61 | $15.82 |
| 52 Week High | $72.35 | $42.00 |
| Indicator | SMG | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 48.24 | 55.01 |
| Support Level | $58.68 | $29.73 |
| Resistance Level | $64.96 | $37.43 |
| Average True Range (ATR) | 2.58 | 1.77 |
| MACD | 0.05 | 0.38 |
| Stochastic Oscillator | 50.14 | 64.34 |
Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The company sells a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.